MMP-9 inhibition: A therapeutic strategy in ischemic stroke

Molecular Neurobiology

Volumn 49, Issue 1, 2014, Pages 563-573

  Chaturvedi, Mayank ^a   Kaczmarek, Leszek ^a  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

Ischemic stroke; MMP inhibitors; MMP 9; Neuronal damage; Neuroprotection; Therapeutic target; TIMP 1

Indexed keywords

ETHYLENEGLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID BIS(2 OCTYLOXYETHYL) ESTER; GELATINASE B; GELATINASE INHIBITOR; MINOCYCLINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VIRUS VECTOR;

BIOLOGICAL THERAPY; BRAIN DAMAGE; BRAIN ISCHEMIA; ENZYME ACTIVITY; ENZYME INHIBITION; GENE SILENCING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INDUCED HYPOTHERMIA; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; TREATMENT PLANNING;

ANIMALS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; NEUROPROTECTIVE AGENTS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84894374325     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8538-z     Document Type: Review

References (108)

1. Towfighi A, Saver JL (2011) Stroke declines from third to fourth leading cause of death in the United States historical perspective and challenges ahead. Stroke 42(8):2351-2355
2. Crunkhorn S (2008) Stroke: widening the therapeutic window? Nat Rev Drug Discov 7(8):643-643
3. The National Institute of Neurological Disorders and Stroke (1995) Tissue plasminogen activator for acute ischemic stroke rt-PA. Study Group 333(24):1581-1587
4. Tilley BC, Lyden PD, Brott TG, Lu M, Levine SR, Welch K (1997) Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Arch Neurol 54(12):1466-1474
5. Durukan A, Tatlisumak T (2008) Animal models of ischemic stroke. Handb Clin Neurol 92:43-66
6. Wang-Fischer Y (2008) Manual of stroke models in rats. CRC, New York
7. Graham SM, McCullough LD, Murphy SJ (2004) Animal models of ischemic stroke: balancing experimental aims and animal care. Comp Med 54(5):486-496
8. Wiebers D, Adams H Jr, Whisnant J (1990) Animal models of stroke: are they relevant to human disease. Stroke 21(1):1-3
9. Cimarosti H, Henley JM (2008) Investigating the mechanisms underlying neuronal death in ischemia using in vitro oxygen-glucose deprivation: potential involvement of protein SUMOylation. Neuroscientist 14(6):626-636
10. Kume T, Nishikawa H, Taguchi R, Hashino A, Katsuki H, Kaneko S, Minami M, Satoh M, Akaike A (2002) Antagonism of NMDA receptors by σ receptor ligands attenuates chemical ischemia-induced neuronal death in vitro. Eur J Pharmacol 455(2):91-100
11. Howells DW, Porritt MJ, Rewell SS, O'Collins V, Sena ES, van der Worp HB, Traystman RJ, Macleod MR (2010) Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. J Cerebr Blood F Met 30(8):1412-1431
12. Rice JE, Vannucci RC, Brierley JB (1981) The influence of immaturity on hypoxic-ischemic brain damage in the rat. Ann Neurol 9(2):131-141
13. Sicard K, Fisher M (2009) Animal models of focal brain ischemia. Exp Transl Stroke Med 1(1):7
14. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Ann Rev Cell Dev Biol 17:463
15. Dzwonek J, Rylski M, Kaczmarek L (2004) Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Lett 567(1):129-135
16. Rivera S, Khrestchatisky M, Kaczmarek L, Rosenberg GA, Jaworski DM (2010) Metzincin proteases and their inhibitors: foes or friends in nervous system physiology? J Neurosci 30(46):15337-15357
17. Huntley GW (2012) Synaptic circuit remodelling by matrix metalloproteinases in health and disease. Nat Rev Neurosci 13(11):743-757
18. Kaczmarek L (2012) MMP-9 inhibitors in the brain: can old bullets shoot new targets? Curr Pharm Des 19(6):1085-1089
19. Rybakowski JK (2009) Matrix metalloproteinase-9 (MMP-9): a mediating enzyme in cardiovascular disease, cancer, and neuropsychiatric disorders. Cardiovascular psychiatry and neurology 2009 (09): Article ID 904836
20. Lakhan SE, Kirchgessner A, Tepper D, Leonard A (2013) Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front Neurol 4
21. George SJ, Johnson JL (2010) In situ zymography. In: Matrix Metalloproteinase Protocols. Springer, pp 271-277
22. Gawlak M, Górkiewicz T, Gorlewicz A, Konopacki FA, Kaczmarek L, Wilczynski GM (2009) High resolution in situ zymography reveals matrix metalloproteinase activity at glutamatergic synapses. Neuroscience 158(1):167-176
23. Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, Davalos A (2003) Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 34(1):40-46
24. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J (2003) Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107(4):598-603
25. Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S (2003) Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 34(9):2165-2170
26. Heo JH, Kim SH, Lee KY, Kim EH, Chu CK, Nam JM (2003) Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Stroke 34(6):48-50
27. Reynolds MA, Kirchick HJ, Dahlen JR, Anderberg JM, McPherson PH, Nakamura KK, Laskowitz DT, Valkirs GE, Buechler KF (2003) Early biomarkers of stroke. Clin Chem 49(10):1733-1739
28. Rosenberg GA, Cunningham LA, Wallace J, Alexander S, Estrada EY, Grossetete M, Razhagi A, Miller K, Gearing A (2001) Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 893(1-2):104-112
29. Planas AM, Sole S, Justicia C (2001) Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis 8(5):834-846
30. Rosell A, Ortega-Aznar A, Alvarez-Sabin J, Fernandez-Cadenas I, Ribo M, Molina CA, Lo EH, Montaner J (2006) Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 37(6):1399-1406
31. Rivera S, Ogier C, Jourquin J, Timsit S, Szklarczyk AW, Miller K, Gearing AJ, Kaczmarek L, Khrestchatisky M (2002) Gelatinase B and TIMP-1 are regulated in a cell- and time-dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia. Eur J Neurosci 15(1):19-32
32. Rosell A, Lo EH (2008) Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 8(1):82-89
33. Lakhan SE, Kirchgessner A, Hofer M (2009) Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 7(1):97
34. Yamashita T, Abe K (2011) Therapeutic approaches to vascular protection in ischemic stroke. Acta Med Okayama 65:219-223
35. Fagan SC, Hess DC, Hohnadel EJ, Pollock DM, Ergul A (2004) Targets for vascular protection after acute ischemic stroke. Stroke 35(9):2220-2225
36. Lee SR, Tsuji K, Lo EH (2004) Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J Neurosci 24(3):671-678
37. Copin JC, Goodyear MC, Gidday JM, Shah AR, Gascon E, Dayer A, Morel DM, Gasche Y (2005) Role of matrix metalloproteinases in apoptosis after transient focal cerebral ischemia in rats and mice. Eur J Neurosci 22(7):1597-1608
38. Lee SR, Lo EH (2004) Induction of caspase-mediated cell death by matrix metalloproteinases in cerebral endothelial cells after hypoxia-reoxygenation. J Cereb Blood F Met 24(7):720-727
39. Kelly PJ, Morrow JD, Ning M, Koroshetz W, Lo EH, Terry E, Milne GL, Hubbard J, Lee H, Stevenson E, Lederer M, Furie KL (2008) Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke 39(1):100-104
40. Yang Y, Candelario-Jalil E, Thompson JF, Cuadrado E, Estrada EY, Rosell A, Montaner J, Rosenberg GA (2010) Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J Neurochem 112(1):134-149
41. Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, Wang X, Lo EH (2006) Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 12(4):441-445
42. Inzitari D, Giusti B, Nencini P, Gori AM, Nesi M, Palumbo V, Piccardi B, Armillis A, Pracucci G, Bono G (2013) MMP-9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death. Stroke
43. Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Kelly PJ (2006) Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. 66(10):1550-1555
44. Sumii T, Lo EH (2002) Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33(3):831-836
45. Yang DY, Pan HC, Chen CJ, Cheng FC, Wang YC (2007) Effects of tissue plasminogen activator on cerebral microvessels of rats during focal cerebral ischemia and reperfusion. Neurol Res 29(3):274-282
46. Zhao BQ, Ikeda Y, Ihara H, Urano T, Fan W, Mikawa S, Suzuki Y, Kondo K, Sato K, Nagai N, Umemura K (2004) Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice. Blood 103(7):2610-2616
47. Kelly MA, Shuaib A, Todd KG (2006) Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp Neurol 200(1):38-49
48. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR (1997) Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 238(1-2):53-56
49. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ (1999) Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 19(6):624-633
50. Gasche Y, Fujimura M, Morita-Fujimura Y, Copin JC, Kawase M, Massengale J, Chan PH (1999) Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 19(9):1020-1028
51. Fujimura M, Gasche Y, Morita-Fujimura Y, Massengale J, Kawase M, Chan PH (1999) Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 842(1):92-100
52. Maddahi A, Chen Q, Edvinsson L (2009) Enhanced cerebrovascular expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 via the MEK/ERK pathway during cerebral ischemia in the rat. BMC Neurosci 10:56
53. Rosell A, Ortega-Aznar A, Alvarez-Sabín J, Fernández- Cadenas I, Ribó M, Molina CA, Lo EH, Montaner J (2006) Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 37(6):1399-1406
54. Amantea D, Corasaniti MT, Mercuri NB, Bernardi G, Bagetta G (2008) Brain regional and cellular localization of gelatinase activity in rat that have undergone transient middle cerebral artery occlusion. Neuroscience 152(1):8-17
55. Morancho A, Rosell A, Garcia-Bonilla L, Montaner J (2010) Metalloproteinase and stroke infarct size: role for anti-inflammatory treatment? Ann N Y Acad Sci 1207:123-133
56. Ramos-Fernandez M, Bellolio MF, Stead LG (2011) Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis 20(1):47-54
57. Wang X, Jung J, Asahi M, Chwang W, Russo L, Moskowitz MA, Dixon CE, Fini ME, Lo EH (2000) Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci 20(18):7037-7042
58. Asahi M, Wang X, Mori T, Sumii T, Jung J-C, Moskowitz MA, Fini ME, Lo EH (2001) Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21(19):7724-7732
59. Svedin P, Hagberg H, Savman K, Zhu C, Mallard C (2007) Matrix metalloproteinase-9 gene knock-out protects the immature brain after cerebral hypoxia-ischemia. J Neurosci 27(7):1511-1518
60. Ludewig P, Sedlacik J, Gelderblom M, Bernreuther C, Korkusuz Y, Wagener C, Gerloff C, Fiehler J, Magnus T, Horst AK (2013) CEACAM1 Inhibits MMP-9-mediated blood-brain-barrier breakdown in a mouse model for ischemic stroke. Circ Res PMID: 23780386:[Epub ahead of print]
61. Rivera S, Tremblay E, Timsit S, Canals O, Ben-Ari Y, Khrestchatisky M (1997) Tissue inhibitor of metalloproteinases-1 (TIMP-1) is differentially induced in neurons and astrocytes after seizures: evidence for developmental, immediate early gene, and lesion response. J Neurosci 17(11):4223-4235
62. Tejima E, Guo S, Murata Y, Arai K, Lok J, van Leyen K, Rosell A, Wang X, Lo EH (2009) Neuroprotective effects of overexpressing tissue inhibitor of metalloproteinase TIMP-1. J Neurotrauma 26(11):1935-1941
63. Fujimoto M, Takagi Y, Aoki T, Hayase M, Marumo T, Gomi M, Nishimura M, Kataoka H, Hashimoto N, Nozaki K (2008) Tissue inhibitor of metalloproteinases protect blood-brain barrier disruption in focal cerebral ischemia. J Cereb Blood Flow Metab 28(10):1674-1685
64. Cheng YD, Al-Khoury L, Zivin JA (2004) Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 1(1):36-45
65. Dong X, Song Y-N, Liu W-G, Guo X-L (2009) Mmp-9, a potential target for cerebral ischemic treatment. Curr Neuropharmacol 7(4):269
66. Hu Q, Chen C, Khatibi NH, Li L, Yang L, Wang K, Han J, Duan W, Zhang JH, Zhou C (2011) Lentivirus-mediated transfer of MMP-9 shRNA provides neuroprotection following focal ischemic brain injury in rats. Brain Res 1367:347-359
67. Souvenir R, Fathali N, Ostrowski RP, Lekic T, Zhang JH, Tang J (2011) Tissue inhibitor of matrix metalloproteinase-1 mediates erythropoietin-induced neuroprotection in hypoxia ischemia. Neurobiol Dis 44(1):28-37
68. Tan HK, Heywood D, Ralph GS, Bienemann A, Baker AH, Uney JB (2003) Tissue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons. Mol Cell Neurosci 22(1):98-106
69. Chaturvedi M, Figiel I, Sreedhar B, Kaczmarek L (2012) Neuroprotection from tissue inhibitor of metalloproteinase-1 and its nanoparticles. Neurochem Int 61(7):1065-1071
70. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC (1998) Matrix metalloproteinase expression increases after cerebral focal ischemia in rats inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29(5):1020-1030
71. Hu Q, Chen C, Yan J, Yang X, Shi X, Zhao J, Lei J, Yang L, Wang K, Chen L (2009) Therapeutic application of gene silencing MMP-9 in a middle cerebral artery occlusion-induced focal ischemia rat model. Exp Neurol 216(1):35-46
72. Mahajan SD, Aalinkeel R, Reynolds JL, Nair B, Sykes DE, Bonoiu A, Roy I, Yong K-T, Law W-C, Bergey EJ (2012) Suppression of MMP-9 expression in brain microvascular endothelial cells (BMVEC) using a gold nanorod (GNR)-siRNA nanoplex. Immunol Invest 41(4):337-355
73. Bonoiu A, Mahajan SD, Ye L, Kumar R, Ding H, Yong KT, Roy I, Aalinkeel R, Nair B, Reynolds JL, Sykes DE, Imperiale MA, Bergey EJ, Schwartz SA, Prasad PN (2009) MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res 1282:142-155
74. Magnoni S, Baker A, Thomson S, Jordan G, George S, McColl B, McCulloch J, Horsburgh K (2007) Neuroprotective effect of adenoviral-mediated gene transfer of TIMP-1 and -2 in ischemic brain injury. Gene Ther 14(7):621-625
75. Sa Y, Hao J, Samineni D, Clark J, Pyne-Geithman G, Broderick J, Lu A (2011) Brain distribution and elimination of recombinant human TIMP-1 after cerebral ischemia and reperfusion in rats. Neurol Res 33(4):433-438
76. Batra J, Robinson J, Mehner C, Hockla A, Miller E, Radisky DC, Radisky ES (2012) PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1). PLoS One 7(11):e50028
77. Guan W, Kozak A, Fagan SC (2011) Drug repurposing for vascular protection after acute ischemic stroke. In: Intracerebral hemorrhage research. Springer, New York, pp 295-298
78. Hess DC, Fagan SC (2010) Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: minocycline. Pharmacotherapy: J Human Pharmacol Drug Ther 30(7P2):55S-61S
79. Sapadin AN, Fleischmajer R (2006) Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54(2):258-265
80. Guerin C, Laterra J, Masnyk T, Golub LM, Brem H (1992) Selective endothelial growth inhibition by tetracyclines that inhibit collagenase. Biochem Biophys Res Commun 188(2):740-745
81. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC (2006) Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci 7(1):56
82. Fagan SC, Cronic LE, Hess DC (2011) Minocycline development for acute ischemic stroke. Transl Stroke Res 2(2):202-208
83. Machado LS, Sazonova IY, Kozak A, Wiley DC, El-Remessy AB, Ergul A, Hess DC, Waller JL, Fagan SC (2009) Minocycline and tissue-type plasminogen activator for stroke assessment of interaction potential. Stroke 40(9):3028-3033
84. Zemke D, Majid A (2004) The potential of minocycline for neuroprotection in human neurologic disease. Clin Neuropharmacol 27(6):293-298
85. Chen X, Chen S, Jiang Y, Zhu C, Wu A, Ma X, Peng F, Ma L, Zhu D, Wang Q (2012) Minocycline reduces oxygen-glucose deprivation-induced PC12 cell cytotoxicity via matrix metalloproteinase-9, integrin β1 and phosphorylated Akt modulation. Neurological Sciences: 1-6
86. Koistinaho M, Malm TM, Kettunen MI, Goldsteins G, Starckx S, Kauppinen RA, Opdenakker G, Koistinaho J (2005) Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab 25(4):460-467
87. Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH (2008) Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke 39(12):3372-3377
88. Lee R (2011) Letter by Lee regarding article, "matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute stroke". Stroke 42(10):e566-e566
89. Fan X, Lo EH, Wang X (2013) Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats. Stroke 44(3):745-752
90. Zhang L, Chopp M, Jia L, Cui Y, Lu M, Zhang ZG (2009) Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats. J Cereb Blood F Met 29(11):1816-1824
91. Jang J-W, Lee J-K, Lee M-C, Piao M-S, Kim S-H, Kim H-S (2012) Melatonin reduced the elevated matrix metalloproteinase-9 level in a rat photothrombotic stroke model. J Neurol Sci 323:221-227
92. Wu Y, Wang Y-P, Guo P, Ye X-H, Wang J, Yuan S-Y, Yao S-L, Shang Y (2012) A lipoxin A4 analog ameliorates blood-brain barrier dysfunction and reduces MMP-9 expression in a rat model of focal cerebral ischemia-reperfusion injury. J Mol Neurosci 46(3):483-491
93. Zhou J, Li J, Rosenbaum DM, Barone FC (2010) Thrombopoietin protects the brain and improves sensorimotor functions: reduction of stroke-induced MMP-9 upregulation and blood-brain barrier injury. J Cereb Blood F Met 31(3):924-933
94. Hosomi N, Nishiyama A, Ban C, Naya T, Takahashi T, Kohno M, Koziol J (2005) Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience 134(1):225-231
95. Candelario-Jalil E, Taheri S, Yang Y, Sood R, Grossetete M, Estrada EY, Fiebich BL, Rosenberg GA (2007) Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-α in the rat. J Pharmacol Exp Therapeut 323(2):488-498
96. Diener HC, Schneider D, Lampl Y, Bornstein NM, Kozak A, Rosenberg G (2008) DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. Stroke 39(6):1774-1778
97. Jiang X-F, Namura S, Nagata I (2001) Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice. Neurosci Lett 305(1):41-44
98. Gu Z, Cui J, Brown S, Fridman R, Mobashery S, Strongin AY, Lipton SA (2005) A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 25(27):6401-6408
99. Ranasinghe HS, Scheepens A, Sirimanne E, Mitchell MD, Williams CE, Fraser M (2012) Inhibition of MMP-9 activity following hypoxic ischemia in the developing brain using a highly specific inhibitor. Dev Neurosci 34(5):417-427
100. Coimbra C, Drake M, Boris-Möller F, Wieloch T (1996) Long-lasting neuroprotective effect of postischemic hypothermia and treatment with an anti-inflammatory/antipyretic drug evidence for chronic encephalopathic processes following ischemia. Stroke 27(9):1578-1585
101. van der Worp HB, Macleod MR, Kollmar R (2010) Therapeutic hypothermia for acute ischemic stroke: ready to start large randomized trials&quest. J Cereb Blood F Met 30(6):1079-1093
102. Wagner S, Nagel S, Kluge B, Schwab S, Heiland S, Koziol J, Gardner H, Hacke W (2003) Topographically graded postischemic presence of metalloproteinases is inhibited by hypothermia. Brain Res 984(1):63-75
103. Nagel S, Su Y, Horstmann S, Heiland S, Gardner H, Koziol J, Martinez-Torres FJ, Wagner S (2008) Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat: effects on BBB breakdown and MMP expression in the acute and subacute phase. Brain Res 1188:198
104. Lee JE, Yoon YJ, Moseley ME, Yenari MA (2005) Reduction in levels of matrix metalloproteinases and increased expression of tissue inhibitor of metalloproteinase-2 in response to mild hypothermia therapy in experimental stroke. J Neurosurg 103(2):289-297
105. Truettner JS, Alonso OF, Dietrich WD (2005) Influence of therapeutic hypothermia on matrix metalloproteinase activity after traumatic brain injury in rats. J Cerebr Blood F Met 25(11):1505-1516
106. Zhao J-K, Guan F-L, Duan S-R, Zhao J-W, Sun R-H, Zhang L-M, Wang D-S (2013) Effect of focal mild hypothermia on expression of MMP-9, TIMP-1, Tau-1 and β-APP in rats with cerebral ischaemia/reperfusion injury. Brain Injury (0):1-9
107. Groysman LI, Emanuel BA, Kim-Tenser MA, Sung GY, Mack WJ (2011) Therapeutic hypothermia in acute ischemic stroke. Neurosurg Focus 30(6):E17
108. Takamiya M, Miyamoto Y, Yamashita T, Deguchi K, Ohta Y, Abe K (2012) Strong neuroprotection with a novel platinum nanoparticle against ischemic stroke-and tissue plasminogen activator-related brain damages in mice. Neuroscience 221:47-55